With no manual calibration or maintenance required, our laboratories are ideal for low throughput, single button operation as well as easy to use software including our patented SIMPLE PCR platform at start: Genedrive plc Annual Report 2017 1 Operational Highlights  Proprietary Genedrive® Hepatitis C (HCV) test submitted for CE marking  Continued positive progress with the US DoD biohazard identifier programme, including extension of programme into next phase  Successful field trials of Genedrive® aquaculture testing programme, performed in collaboration with the Centre for Environment, Fisheries and Aquaculture Science (Cefas)  Disappointing uptake of MTB/RIF assay in India, in part owing to sample preparation problems specific to MTB and commercial issues  Name change from Epistem Holdings Plc to genedrive plc and £6m raised from July 2016 placing - strategic focus on molecular diagnostics business opportunities Financial Highlights Post Year End  CE marking obtained for Genedrive® HCV ID kit  Entered into a distribution agreement with Sysmex Europe for Genedrive® HCV ID kit in the EMEA region with an initial focus on Africa  Entered into the next stage of the US DoD biohazard programme, worth approximately $1.4m in development income and a further $0.5m in product sales all expected to be recognised in the current financial year  £0.6m conditional grant offer from Innovate UK to fund centrifuge free plasma separation device £5.8m (2016: £5.1m +13.7% 2016: Revenue and other income (2016: £5.1m) £3.2m +3.2% Service Income (2016: £3.1m) £3.1m (2016: £3.1m) £3.1m (2016: £3.1m) £3.1m (2016: £3.1m) £3.1m (2016: £3.1m) £3.1m (2016: £3.1m (2016: £3.1m) £3.